56 results about "Solid Neoplasm" patented technology

PCT No. PCT/US97/11564 Sec. 371 Date Apr. 14, 1999 Sec. 102(e) Date Apr. 14, 1999 PCT Filed Jul. 8, 1997 PCT Pub. No. WO98/01132 PCT Pub. Date Jan. 15, 1998The present invention relates to specific adamantyl or adamantyl group derivative containing retinoid compounds induce apoptosis of cancer cells. These adamantyl retinoid derivatives are useful for the treatment of many cancers and solid tumors, especially androgen-independent prostate cancer, skin cancer, pancreatic carcinomas, colon cancer, melanoma, ovarian cancer, liver cancer, small cell lung carcinoma, non-small cell lung carcinoma, cervical carcinoma, brain cancer, bladder cancer, breast cancer, neuroblastoma/glioblastoma, and leukemia. Also, the invention relates to novel adamantyl or adamantyl group derivative compounds which are useful as active agents for the treatment or prevention of keratinization disorders and other dermatological conditions, and other diseases.

An efficient angiogenesis depressant HM-3 for treating the solid tumors including stomach cancer, lung cancer and liver cancer is prepared through expressing in colibacillus by genetic engineering method, separating the protein of inclusion body, dissolving, re-naturalizing, and separating-purifying by ion change and chromatography.

The invention relates to a preparation method of a CAR-T cell targeting B7H3. The preparation method includes first preparing a PBMC cell; then co-transfecting a 293T cell with a shuttle plasmid LV-B7H3 containing the CAR structure, a helper plasmid psPAX2 and an envelope plasmid VSV-G to obtain a packaged B7H3-CAR virus; then taking a PBMC cell, using anti-human CD3 and anti-human CD28 as activators, culturing and activating for 48 hours and adding the B7H3-CAR virus for infection. By means of the preparation scheme, the expression of IFN-gamma in the CAR-T cell is increased, and the cell killing activity is high. The CAR-T cell targeting B7H3 has a killing effect on various solid tumor cells, has high killing activity, is safe and effective, and can be used for immunotherapy of kidney cancer, lung cancer, liver cancer, glioma, ovarian cancer, breast cancer and the like.

The invention provides a traditional Chinese medicinal composition for treating lung cancer, and belongs to the technical field of traditional Chinese medicines. Against the problem that current medicaments cannot be used for effectively treating lung cancer, the invention provides the traditional Chinese medicinal composition consisting of pseudo-ginseng, lucid ganoderma, tripterygium wilfordii, ginseng, rhizoma calami, pangolin, common andrographis herb, angelica and liquorice. The traditional Chinese medicinal composition is good in anti-cancer activity in the field of treating lung cancer and other solid tumors, and can be used as a medicament for treating lung cancer.

The invention relates to a method for preparing Lonicera macranthoides saponin and its application in treating liver cancer, breast cancer and carvical carcinoma. Said method comprises following steps: extracting Lonicera macranthoides and bud with ethanol, decoloring with active carbon, grading in macroreticular resinous column or polyamide column, washing with ethanol, basic hydrolyzing, decoloring with active carbon for the second time, crystallizing and getting said product. The invention is characterized by high productivity and purity of effective component, which is about 98%, and is especially for large- scale production. The effective dosage of Lonicera macranthoides saponin is toxic to external cancer cell, and inhibitive to mouse liver cancer H22, mouse S180 cancer and Lewis lung cancer.

Methods for treating proliferative disorders, by administering reovirus to a ral-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts target cancer cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), other serotypes or strains of reovirus, and recombinant reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.

An oleum fructus bruceae fat emulsion concentrated solution, a preparation method and an application thereof belong to the field of pharmacology and pharmaceutics. According to the invention, the defect that a traditional fat emulsion preparation technology is complex and stability is poor is overcome. The preparation technology provided by the invention is simple; the general physical stirring process is only needed; and no homogenization technology is required. A product prepared in the invention can be sterilized through a 0.22-micron microfiltration membrane; in clinical use, the product can be spontaneously emulsified after diluted by the use of an aqueous solution such as normal saline or a glucose solution, etc. and slightly oscillated; and under optimized conditions, average particle size is about 0.2 micron, and injection fat emulsion characteristics are fully embodied. The product has good fluidity, will not be retained on the wall, is single-phase, transparent and clear in appearance, can undergo clarification detection, will not cause preparation stratification after multigelation and is used for treating diseases such as stomach cancer, esophagus cancer, primary hepatic carcinoma, colorectal cancer, pancreas cancer, lung cancer, cervical carcinoma, bladder cancer, prostate cancer and other solid tumor metastatic cancer, etc.

The invention discloses a method for preparing a Fissistigma oldhamii lactam alkali compound and application thereof to preparing an anti-tumour medicine. The method comprises the following steps of: taking Fissistigma oldhamii powder, repetitively extracting the Fissistigma oldhamii powder by using 80% ethanol till the colour of extract becomes thin, recovering the ethanol, and evaporating and drying the extract; dissolving the extract by using water, ultrasonically fluxing the extract, and extracting and decolouring the extract by using petroleum ether till the colour of the extract of the petroleum ether becomes clear; extracting the extract by using dichloromethane till the colour becomes clear, mixing dichloromethane extract, and recovering the dichloromethane to obtain extract; and applying the extract on a silicagel column, eluting the extract by using dichloromethane-methanol, and collecting eluent in a sectional manner to obtain the compound. A characteristic plant in Guizhou, namely kopje Fissistigma oldhamii, has obvious inhibitory activity on neovascularisation; a plurality of active compounds are separated from the Fissistigma oldhamii; experiments prove that the compound not only can inhibit formation of neovascularisation but also has an inhibitory action on tumour cell strains; furthermore, found from animal internal anti-cancer experiments, the compound has obvious anti-tumour activity on a plurality of solid tumours and lung cancers.

The invention discloses a novel benzo [b][1, 8]-naphthyridine-2-(1H)-imide derivative which has antitumor activity, and in particular relates to anti-solid tumor activity and more accurately the anti-lung cancer and anti-colon cancer activity as well as a structure shown in formula (I). The invention further discloses a synthetic method. In formula (I), n is 1, 2 or 3, but R, R1, R2, R3 and R4 are defined as in claim 1. The synthetic method comprises the step of heating a 2-halogen-3-formyl quinoline compound with a structure in formula (II) and a compound with a structure in formula (III) in an appropriate solvent in the presence of a catalyst so as to obtain a target product in formula (I).

A nimustine slow release injection for treating solid cancer comprises slow release finding and nimustine, or the combination of nimustine and relative booster (pidorubicin, osaliplatinum, adriablastina, amethopterin or the like). The viscidity of slow-release injection is 10-650cp (20-30Deg. C). The anti-cancer effective component can be made into slow release plant agent. The slow release finding substantially comprises macromolecule polymer with biological soluble degradable and absorb property, which can slow release the anti-cancer effective component to cancer part in the degradation process, significantly reduce general reaction and hold effective drug density on cancer. The anti-cancer compound can be arranged part of cancer to reduce the general toxicity reaction, selectively improve the drug density locally, and strengthen the effect of non-surgery treatments as chemotherapy, and radiation therapy or the like. The solid cancer comprises glioma, lung carcinoma, intestinal cancer, breast cancer or the like.

A method of treating a solid tumor in a mammal by inhibiting angiogenesis, including administering to the mammal which has a solid tumor selected from the group consisting of breast carcinoma, lung carcinoma, prostate carcinoma, colon carcinoma, ovarian carcinoma, neuroblastoma, central nervous system tumor, multiform glioblastoma and melanoma; a composition including brassinosteroids of general formula (I)

wherein can be a single or double bond and the configurations of carbon atoms C22 and C23 respectively linked to the substituents HO are S for both carbon atoms and a pharmaceutically acceptable additive.

The invention relates to an emodin quaternary phosphonium salt derivative with antitumor activity, a synthesis method therefor and an application of the emodin quaternary phosphonium salt derivative. The emodin quaternary phosphonium salt derivative is {10-[(4,5-dihydroxyl-7-methyl-9,10-anthraquinon-2-yl)oxo]decyl}phosphonium triphenylbromide. Proven by experiments, the emodin quaternary phosphonium salt derivative plays a certain role in inhibiting leukemia cells and solid tumor cells and can be used for preparing antitumor drugs. The emodin quaternary phosphonium salt derivative with antitumor activity, the synthesis method therefor and the application of the emodin quaternary phosphonium salt derivative have the following advantages that the synthesis method for the emodin quaternary phosphonium salt derivative, disclosed by the invention, is simple and is moderate in conditions; shown by the experiments, the emodin quaternary phosphonium salt derivative plays a certain role in inhibiting tumor cells, particularly HL-60 cells, Molt-4 cells, human chronic medullary system leukemia cell line K-562 cells, PANC-1 cells, Bax-PC3 cells, human liver cancer cells HepG2 and human lung cancer cells A549; and lipophilic emodin quaternary phosphonium salts have an application prospect in becoming anticancer drugs.

The present invention relates to a medicine for curing carcinoma of stomach and its preparation method. Said medicine includes antibody and radioactive nuclide. Said antibody is monoclonal antibody 3H11, said radioactive nuclide can utilize a bifunctional connecting agent to mark the described monoclonal antibody 3H11. Because the tumor cell surface can express specific antigen, so that it can utilize the specific combination of antibody and antigen, and can utilize antibody to make the radioactive nuclide be loaded on the tumor region, and utilize beta-particles released by radioactive nuclide decay to kill carcinoma cell so as to attain the goal of curing carcinoma.

The invention discloses a 2-amino-4-indolyl pyrimidine compound as well as a preparation method and application thereof, and belongs to the technical field of medicine synthesis. In particular to pyrimidine compounds, stereoisomers or pharmaceutically acceptable salts thereof, preparation methods of the pyrimidine compounds and the stereoisomers or the pharmaceutically acceptable salts thereof, and application of the pyrimidine compounds and the stereoisomers or the pharmaceutically acceptable salts in antitumor drugs. Pharmacological experiment results show that the compound can inhibit proliferation of various tumor cells, and the cancer or tumor related diseases comprise various solid tumors and hematoma such as brain glioma, pituitary tumor, glioma, melanoma, breast cancer, lung cancer, stomach cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer, prostate cancer, testicular cancer, multiple myeloma, leukemia and the like. The compound provided by the invention is expected to be developed into a new generation of anticancer drugs.

The present invention relates to novel imidazo[1,2-b]pyrazole carboxamide and carbothioamide derivatives of general formula (V), and the advantageous derivatives and pharmaceutically acceptable salts thereof, the synthesis thereof, and medicinal and/or pharmaceutical composition comprising these compounds thereof and synthesis thereof, and for use as a medicament, for use in the treatment of different diseases, advantageously of cancer. The subject compounds are advantageously for use in the treatment of solid malignancies, advantageously breast, lung, melanoma, gliomas, and myeloproliferative and myelodysplastic neoplasms, acute myelogenous/myeloid leukemias and colon cancer by the differentiation and subsequent apoptosis of pre-matured myeloid leukemic cells or myeloid-derived suppressor cells and/or by direct effect on solid tumors.